We describe the only case we are aware of where molecular analysis and in vitro high throughput drug screening (HTS) aided treatment decision making by suggesting resistance to conventional, yet toxic, treatment regimens and identified a tolerable, novel targeted therapy in a patient with ETV6‐MECOM fusion‐positive refractory AML. This evidence concerns the gene ETV6 and acute myeloid leukemia.